Download MendeleyDesign and Synthesis of Acyclic Boronic Acid Arginase Inhibitors.
Shields, J.D., Aquila, B.M., Emmons, D., Finlay, M.R.V., Gangl, E.T., Gu, C., Mlynarski, S.N., Petersen, J., Pop-Damkov, P., Sha, L., Simpson, I., Tavakoli, S., Tentarelli, S., Wang, H., Ye, Q., Zheng, X.(2024) J Med Chem 67: 20799-20826
- PubMed: 39540340 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.4c02295
- Primary Citation Related Structures:
8RIM, 9FRV - PubMed Abstract:
Arginase has long been a target of interest in immuno-oncology, but discovering an orally bioavailable inhibitor is severely constrained by the requisite boronic acid pharmacophore. We began our drug discovery campaign by building off the β-position of the literature inhibitor ABH ( 1 ). A divergent synthesis with an Ireland-Claisen rearrangement as the key step allowed access to numerous compounds, some of which we crystallized in the active site of arginase 2. We subsequently used structure-based drug design to further improve the potency of this series, ultimately achieving an inhibitor with an IC 50 value of 12 nM. Many compounds in this series were designed to behave as prodrugs, releasing their payload with up to 4-fold improved oral exposure relative to the parent. Subtle stereochemical differences between these various inhibitors and prodrugs had substantial effects on potency and pharmacokinetics.
- Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Organizational Affiliation:
